{"id":"https://openalex.org/W7204698006","doi":"https://doi.org/10.1016/s2152-2650(26)02385-2","title":"MPN-1053: Design Verification Testing of a Highly Sensitive Multiplex qPCR Assay That Detects the JAK2 V617F Variant Commonly Present in Myeloproliferative Neoplasms","display_name":"MPN-1053: Design Verification Testing of a Highly Sensitive Multiplex qPCR Assay That Detects the JAK2 V617F Variant Commonly Present in Myeloproliferative Neoplasms","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204698006","doi":"https://doi.org/10.1016/s2152-2650(26)02385-2"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)02385-2","doi":"https://doi.org/10.1016/s2152-2650(26)02385-2","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02385-2","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067531907","display_name":"Jonathan Turner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149757","display_name":"R&D Systems (United States)","ror":"https://ror.org/05k887p27","country_code":"US","type":"company","lineage":["https://openalex.org/I4210149757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Turner","raw_affiliation_strings":["Bio-Techne, Austin, TX, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bio-Techne, Austin, TX, United States of America","institution_ids":["https://openalex.org/I4210149757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148732714","display_name":"Jamie Myers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149757","display_name":"R&D Systems (United States)","ror":"https://ror.org/05k887p27","country_code":"US","type":"company","lineage":["https://openalex.org/I4210149757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jamie Myers","raw_affiliation_strings":["Bio-Techne, Austin, TX, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bio-Techne, Austin, TX, United States of America","institution_ids":["https://openalex.org/I4210149757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148753681","display_name":"Cale Heiniger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149757","display_name":"R&D Systems (United States)","ror":"https://ror.org/05k887p27","country_code":"US","type":"company","lineage":["https://openalex.org/I4210149757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cale Heiniger","raw_affiliation_strings":["Bio-Techne, Austin, TX, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bio-Techne, Austin, TX, United States of America","institution_ids":["https://openalex.org/I4210149757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5116648902","display_name":"Mahesh Yarasi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149757","display_name":"R&D Systems (United States)","ror":"https://ror.org/05k887p27","country_code":"US","type":"company","lineage":["https://openalex.org/I4210149757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mahesh Yarasi","raw_affiliation_strings":["Bio-Techne, Austin, TX, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bio-Techne, Austin, TX, United States of America","institution_ids":["https://openalex.org/I4210149757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108621795","display_name":"Kevin Kelnar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149757","display_name":"R&D Systems (United States)","ror":"https://ror.org/05k887p27","country_code":"US","type":"company","lineage":["https://openalex.org/I4210149757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Kelnar","raw_affiliation_strings":["Bio-Techne, Austin, TX, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bio-Techne, Austin, TX, United States of America","institution_ids":["https://openalex.org/I4210149757"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016766338","display_name":"John N. Milligan","orcid":"https://orcid.org/0000-0002-8905-8318","observed_orcids":["https://orcid.org/0000-0002-8905-8318"]},"institutions":[{"id":"https://openalex.org/I4210149757","display_name":"R&D Systems (United States)","ror":"https://ror.org/05k887p27","country_code":"US","type":"company","lineage":["https://openalex.org/I4210149757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John N Milligan","raw_affiliation_strings":["Bio-Techne, Austin, TX, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bio-Techne, Austin, TX, United States of America","institution_ids":["https://openalex.org/I4210149757"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110221628","display_name":"Brian C. Haynes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149757","display_name":"R&D Systems (United States)","ror":"https://ror.org/05k887p27","country_code":"US","type":"company","lineage":["https://openalex.org/I4210149757"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian C Haynes","raw_affiliation_strings":["Bio-Techne, Austin, TX, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bio-Techne, Austin, TX, United States of America","institution_ids":["https://openalex.org/I4210149757"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210149757"],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S805","last_page":"S806"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11970","display_name":"Molecular Biology Techniques and Applications","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11314","display_name":"Clinical Laboratory Practices and Quality Control","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiplex-qpcr-assay","display_name":"multiplex qPCR assay","score":0.8029999732971191},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.972000002861023},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.9919999837875366},{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":0.9769999980926514},{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":0.9959999918937683},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.6740000247955322},{"id":"https://openalex.org/keywords/analytical-sensitivity","display_name":"analytical sensitivity","score":0.640999972820282},{"id":"https://openalex.org/keywords/detection-limit","display_name":"detection limit","score":0.5220000147819519},{"id":"https://openalex.org/keywords/variant-allele-frequency","display_name":"variant allele frequency","score":0.6729999780654907},{"id":"https://openalex.org/keywords/bone-marrow-aspirate","display_name":"bone marrow aspirate","score":0.6869999766349792},{"id":"https://openalex.org/keywords/whole-blood-dna","display_name":"whole blood DNA","score":0.7639999985694885},{"id":"https://openalex.org/keywords/assay-validation","display_name":"assay validation","score":0.4359999895095825}],"concepts":[{"id":"https://openalex.org/C2909272587","wikidata":"https://www.wikidata.org/wiki/Q14914514","display_name":"JAK2 V617F","level":4,"score":0.7768999934196472},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7574999928474426},{"id":"https://openalex.org/C2781188995","wikidata":"https://www.wikidata.org/wiki/Q6934982","display_name":"Multiplex","level":2,"score":0.7329000234603882},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.4196999967098236},{"id":"https://openalex.org/C2910274570","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative Disorders","level":2,"score":0.3917999863624573},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3395000100135803},{"id":"https://openalex.org/C2908731994","wikidata":"https://www.wikidata.org/wiki/Q2509220","display_name":"Hematologic Neoplasms","level":3,"score":0.30559998750686646},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.2840999960899353},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.2736999988555908},{"id":"https://openalex.org/C90583042","wikidata":"https://www.wikidata.org/wiki/Q1952456","display_name":"Multiplex polymerase chain reaction","level":4,"score":0.27219998836517334},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.2669000029563904},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.2630000114440918},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.2615000009536743}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(26)02385-2","doi":"https://doi.org/10.1016/s2152-2650(26)02385-2","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02385-2","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2157114147","https://openalex.org/W1953531981","https://openalex.org/W7036888452","https://openalex.org/W7093121703","https://openalex.org/W2034610539","https://openalex.org/W7171299514","https://openalex.org/W7018389274","https://openalex.org/W2411818090","https://openalex.org/W2148366180","https://openalex.org/W3025976664"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2026-08-31T00:00:00"}